Transforming Molecular Diagnostics
Rapid and comprehensive detection of pathogens is an important strategy in reducing the spread of infectious disease. Our EasyScreen™ Detection Kits identify a larger number of pathogen targets in a shorter time frame than conventional methods.
Traditional techniques for identifying viral, bacterial and protozoan pathogens require a high degree of knowledge and can take days to get a result. Our EasyScreen™ Detection Kits replace these methodologies with a single efficient workflow that requires less training, staff and hands-on-time, and gives a result in under 5 hours.
The Genetic Signatures GS1 platform is a high-throughput bench top platform that performs both nucleic acid extraction and automated 384-well PCR set-up for the entire EasyScreen™ range. Our EasyScreen™ Detection Kits are also compatible with most existing automated nucleic acid extraction and real-time PCR instruments.
Our EasyScreen™ Sample Processing Kits offer streamlined preparation of nucleic acids direct from the primary specimen. Our sample processing method is common for all specimen types leading to workflow efficiencies and standardised results between laboratories.
Our 3base™ technology forms the basis of the EasyScreen™ Detection Kits. 3base™ allows for simpler design of molecular assays facilitating the simultaneous detection of multiple targets. 3base™ is compatible with both RNA and DNA targets.
Genetic Signatures has a number of new detection kits in development. All new products follow a defined development and commercialisation process comprised of (i) Experimental Analytical Validation, and (ii) Clinical and Regulatory Validation prior to release.
Genetic Signatures will be exhibiting at the 33rd ASM Clinical Virology Symposium (CVS) Savannah, Georgia, United States, 07-10 May 2017. Presented by ASM- The Clinical Virology Symposium is a 3-day…
GenomeWeb, the largest online newsroom focused on advanced molecular research tools, has featured Genetic Signatures and 3base™ technology, in an article about the company’s continued global market rollout of their existing…
Quarterly Cash Flow and Activities Report – GSS Appendix 4C 31 March 2017
Genetic Signatures presents clinical trial results of EasyScreenTM Flavivirus/Alphavirus detection kit at ECCMID 2017